The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.

Naohiro FujimotoYujiro NagataMasaki ShiotaAkinori MinatoIkko TomisakiKenichi HaradaHiroshi Miyamoto

Published in: In vivo (Athens, Greece) (2024)

Patients with low-risk and/or low-volume mCSPC showed long-term survival when undetectable PSA was achieved during conventional ADT. In these patients, skipping upfront treatment intensification does not seem to negatively impact survival.

Keyphrases

prostate cancer
radical prostatectomy
end stage renal disease
squamous cell carcinoma
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
mass spectrometry
rectal cancer
high resolution
adipose tissue
minimally invasive
patient reported outcomes